IPATH has just received FDA approval to start its first clinical trial! This will be the first US trial involving intravenous (IV) phage treatment, and will be a collaboration with Ampliphi Biosciences.
Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.
A phase II clinical trial for a phage lysin has been deemed successful! An anti-Staphylococcus aureus phage lysin, called exebacase, was just found to be both safe and effective at treating MRSA in patients. Exebacase is being developed by ContraFect using technology licensed from Rockefeller University.
The phage therapy biotech company Ampliphi Biosciences is merging with C3J Therapeutics, a synthetic phage/antimicrobial engineering company.
Due to the partial U.S. government shutdown, ASM is extending the deadline for ASM Microbe abstract submissions to January 25, 2019.
Thanks to support from Roche Molecular Diagnostics and Intralytix, ASM Division M will provide 4 travel awards to students presenting phage work at ASM Microbe 2019! To apply, use “phage” as a keyword in your submitted abstract. Before you do, go to http://myasm.asm.org to become a Division M (Bacteriophage) member, as preference for awards is given to students who are members (and whose mentors are too).
No new jobs this week. If you’d like to add one, please post one by emailing [email protected]
We’d like to have answers for people when they visit our site, so we’re building a Phage Therapy FAQ page. To maximize the info we can provide, we’re going to link to other phage therapy FAQ pages whenever possible. We’d also like to draw upon the phage community (all of you) for help.
If you have a bacterial infection, and it will not respond to antibiotics, you could be eligible for phage therapy. In most countries, phage therapy remains an experimental treatment, and thus must be done according to experimental treatment guidelines (which vary according to the country you’re in).
Phage therapy must always be supervised by a licensed physician, and in most countries, the physician will have to work with the national regulatory body to apply for approval to treat your infection with phages. You will need to know the identity of the bacteria causing your infection, which generally requires that the bacteria causing your infection are cultured.
There are only a few established phage therapy centers in the world, and many patients travel thousands of miles to be treated at these centers. If a person does not wish to or cannot travel for treatment, phage therapy can sometimes be set up to occur at a patient’s local clinic or hospital.
DISCLAIMER: We cannot and do not give medical advice. The information we provide here is intended to help you understand the process a little bit more and to help direct you to professionals who can help you learn if phage therapy is right for you. All decisions to pursue or proceed with phage therapy must be done under the direct supervision of a licensed physician.
Thanks for reading!
For every issue of Capsid & Tail, we are committed to getting our facts straight, but we’re not experts in the information we’re bringing to you. If you feel that we’ve missed an important viewpoint, or if you have something to add, please reach out to us by emailing [email protected]. We’d love to hear from you, and we’d be happy to revisit topics we’ve covered (ideally with added information and viewpoints from community members like you!).
Lastly, please reach out if you’re interested in writing for us, or have suggestions for future issues!